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Global prevalence of age-related macular degeneration
The Global Burden of Disease Study 2010 revealed 
that increasing population sizes, substantial in-
creases in the average age in most world regions, 
and falling death rates have all led to a transition in 
the burden of disease towards disorders that cause 
disability but not substantial mortality.1–4 Age-related 
macular degeneration is one of these disabling and 
degenerative diseases, mostly targeting elderly 
people. In 2010, an estimated 32·4 million people 
were blind (defined as presenting visual acuity of 
less than 3/60), and roughly 191 million people had 
moderate-to-severe vision impairment (defined 
as presenting visual acuity of less than 6/18 but 
equal to or better than 3/60).5 Although the age-
standardised prevalence of blindness for older adults 
decreased from 3·0% in 1990 to 1·9% in 2010, and 
visual impairment decreased from 14·3% to 10·4%, 
the number of blind people increased by 0·6 million 
and the number of visually impaired people increased 
by 19 million. This tendency was due to the increase 
in the global population size and mean population 
age.5 In both 1990 and 2010, macular degeneration—
mainly age-related—was the third most common 
cause of blindness (6·6% of all cases in 2010).6 It 
was also the third most common cause for visual 
impairment, accounting for 3·1% of all cases.6 From 
1990 to 2010, the prevalence of blindness and visual 
impairment due to macular degeneration increased, a 
trend that will further continue until a prophylaxis or 
a markedly effective therapy has been developed. 
The study by Wan Ling Wong and colleagues7 
examines the overall prevalence of age-related 
macular degeneration. In agreement with previous 
studies, Wong and colleagues have projected that 
196 million people will be aﬀ ected by age-related 
macular degeneration in 2020, increasing to 
288 million by 2040.7 Their meta-analysis contributes 
to existing evidence by summarising and critically 
weighing up all available and reliable information on 
prevalence. However, questions still remain. Although 
the prevalence of a disease is interesting, it is not as 
important as knowing the overall disease burden. The 
authors do not report on visual acuity or the eﬀ ect 
of vision loss on the quality of vision and quality of 
life. This aspect might be addressed in a future study. 
Another question refers to the factors associated 
with age-related macular degeneration and whether 
spectrum and inﬂ uence of these factors diﬀ ers between 
countries. In a similar manner, the question arises of 
why its prevalence varies between regions. The answers 
to these questions could help in the prevention of the 
disease, in elucidating the pathogenesis, and could 
give hints for the development of new therapeutic 
procedures.
As with any study, this investigation has its 
limitations. A major inevitable limitation of such a 
study is that polypoidal vascular choroidopathy cannot 
reliably be diﬀ erentiated from the exudative (wet) 
form of age-related macular degeneration.8 Since 
polypoidal vascular choroidopathy is markedly more 
common in Asia than in Europe, the prevalence of the 
exudative (late) form might have been overestimated 
for the Asian regions in Wong and colleagues´ meta-
analysis, a point that is discussed by the authors. 
Therefore, rates of the both early and late type of 
age-related macular degeneration were possibly less 
frequent in the Asian populations than in the European 
populations assessed. Another limitation is that optical 
coherence tomography, a fairly new technique, was 
not applied in the preceding studies underlying the 
meta-analysis. Since optical coherence tomography 
is more precise in detecting morphological changes 
in the macula than the conventional procedure of 
examining fundus photographs, the prevalence of 
age-related macular degeneration might have been 
underestimated. Another unavoidable limitation of 
the study is that future developments might provide 
new therapies or prophylactic procedures that will 
reduce the number of patients aﬀ ected by age-related 
macular degeneration. Finally, although macular 
degeneration, mainly age-related, was estimated to be 
the cause of 7% of blindness and 3% visual impairment 
worldwide, cataract and undercorrection of refractive 
error represented more than 50% of all cases. As 
devastating as the eﬀ ect that age-related macular 
degeneration has on the quality of vision and quality of 
life, global public health measures that provide glasses 
and cataract surgery are by far more successful, safer, 
and more cost-eﬀ ective than any therapy previously 
available for age-related macular degeneration. 
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